|
Title
|
|
|
|
Telavancin
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| In September 2009, telavancin (Vibativ; Theravance/Astellas Pharma), a lipoglycopeptide antibiotic, was approved by the US FDA for the treatment of adult patients with complicated skin and skin structure infections. |
| |
|
Language
|
|
|
|
French
| |
|
Source (journal)
|
|
|
|
Nature reviews drug discovery
| |
|
Publication
|
|
|
|
2009
| |
|
DOI
|
|
|
|
10.1038/NRD3051
| |
|
Volume/pages
|
|
|
|
8
:12
(2009)
, p. 929-930
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|